A Phase 1 Study of IL-15 Superagonist (N-803) and Broadly Neutralizing Antibodies to Induce HIV-1 Control

Brief description of study

This study will investigate whether N-803, a new experimental drug that stimulates the immune system, is safe and tolerable when given alone and in combination with two new experimental drugs that are antibodies (natural proteins that the body makes in response to an infection) to HIV (the virus that causes AIDS), VRC07-523LS and 10-1074.

Detailed description of study

Study duration: 100-112 weeks

Additional Information

Participants must be willing to participate in analytic treatment interruption (ATI)

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
HIV,antiretroviral,analytic treatment interruption
Age: Between 18 Years - 70 Years
Gender: All

Individuals living with HIV on ART with a viral load <50 copies/mL for at least 96 weeks.

Lowest CD4 count > 200 cells/mm3

Updated on 09 Mar 2024. Study ID: 848907

Pre-Screener

Check if you are eligible Enter contact details Select a study center

Are you living with HIV?

Yes No Maybe